Thomas Catinazzo - 08 Sep 2022 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role: Chief Financial Officer
Signature: /s/ Brian Adams, as Attorney-in-Fact
Issuer symbol: RLAY
Transactions as of: 08 Sep 2022
Net transactions value: -$679,531
Form type: 4
Filing time: 08 Sep 2022, 20:26:49 UTC
Previous filing: 29 Jul 2022
Next filing: 29 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RLAY	Common Stock	Options Exercise	$108,179	+26,257	+50%	$4.12	78,475	08 Sep 2022	Direct	F1, F2
transaction	RLAY	Common Stock	Sale	$787,710	-26,257	-33%	$30.00	52,218	08 Sep 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RLAY	Stock Option (Right to Buy)	Options Exercise	$0	-26,257	-100%	$0.000000^*	0	08 Sep 2022	Common Stock	26,257	$4.12	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021.
F2	Includes 45,273 shares underlying restricted stock units.
F3	Twenty-five percent (25%) of the shares underlying this option vested on April 9, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.